News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INNOVIVE Pharmaceuticals Initiates Pivotal Phase II Clinical Trial with Tamibarotene



11/15/2007 9:07:35 AM

NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that the first patient has been treated in a pivotal Phase II clinical trial evaluating oral Tamibarotene for the treatment of refractory acute promyelocytic leukemia (APL). APL is a type of acute myeloid leukemia. This trial will be conducted under a Special Protocol Assessment (SPA) agreed upon by INNOVIVE and the U.S. Food and Drug Administration (FDA) in August. In conjunction with data from Japanese studies, data from INNOVIVE’s pivotal study of Tamibarotene are expected to form the basis of a New Drug Application (NDA) with the FDA.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES